Ajinomoto Bio-Pharma Services Awarded Two ‘CMO Leadership Awards’
March 3, 2022 – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, received two CMO Leadership Awards in the categories Expertise and Service for Big Pharma.
“We are extremely pleased to be recognized by our partners. Aji Bio-Pharma has continued to invest in new technologies, quality systems, and, most importantly, our people to increase our capabilities and capacities to meet the needs of our valued clients. In doing so, we further contribute to improving and extending the lives of patients with the drugs we produce.” said Nobu Shimba, CEO, Ajinomoto Bio-Pharma Services US.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners. The awards are presented by Life Science Leader magazine and Industry Standard Research (ISR). The winning CMOs are chosen through impartial market research based on feedback from sponsor companies that utilize outsourcing services. More than 86 contract manufactures were assessed by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Based on ratings of recent outsourced projects provided by sponsors, this experiential feedback is analyzed by sponsor company size to reveal leading CMOs in different performance categories.
Mark Cassidy, CEO, Ajinomoto Bio-Pharma Services EU, stated, “This award is especially meaningful for us as we take great pride in providing personalized service and the expertise to meet our clients’ needs in delivering quality products. For the last 30 years, some of the largest bio-pharma companies have entrusted us to supply product for billions of doses of life saving medicines and thereby realize our mission to help improve the health of humankind.”
“For nearly a decade, these awards have proven most meaningful for biopharma organizations striving to obtain optimal outcomes from their outsourcing activities. Our research arm, Industry Standard Research (ISR), which only surveys drug sponsors who have worked recently with specific CDMOs, ensures the validity of these results. Our winners will be your champions of outsourcing.” Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma.
À propos d'Ajinomoto Bio-Pharma Services
Ajinomoto Bio-Pharma Services est une organisation de développement et de fabrication sous contrat (CDMO) entièrement intégrée, disposant de sites en Belgique, aux États-Unis, au Japon et en Inde. Elle propose des services complets de développement, de fabrication conforme aux normes cGMP et de conditionnement aseptique pour les principes actifs pharmaceutiques (API) de petite et grande taille ainsi que pour les intermédiaires. Ajinomoto Bio-Pharma Services propose un large éventail de plateformes et de capacités innovantes, allant des programmes précliniques et pilotes jusqu’aux quantités commerciales, notamment la technologie d’expression protéique Corynex®, la synthèse d’oligonucléotides, les conjugués anticorps-médicaments (ADC), les principes actifs pharmaceutiques à haute puissance (HPAPI), la biocatalyse, la fabrication en flux continu et bien plus encore. Ajinomoto Bio-Pharma Services s’engage à fournir un niveau élevé de qualité et de service afin de répondre aux besoins de ses clients. Pour en savoir plus : www.AjiBio-Pharma.com
